Premium
Discovery of Oligosaccharide Antigens for Semi‐Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14 **
Author(s) -
Zhang Shuo,
Sella Mauro,
Sianturi Julinton,
Priegue Patricia,
Shen Dacheng,
Seeberger Peter H.
Publication year - 2021
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.202103990
Subject(s) - streptococcus suis , glycoconjugate , serotype , microbiology and biotechnology , glycan , virulence factor , virulence , antigen , bacteria , oligosaccharide , biology , virology , glycoprotein , immunology , gene , biochemistry , genetics
Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi‐synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.